Document is current

Article History

Received: 15 July 2021

Accepted: 23 February 2022

First Online: 23 March 2022

Competing interests

: K.V.P. is funded by NIA grant K23 AG053422-01 and the Alzheimer’s Association and has served as a paid consultant for Biogen. A.P.S. has been a paid consultant for Janssen, Biogen, Qynapse, and NervGen. D.M.R. has done consulting for Biogen, Idec and Digital Cognition Technologies and served on the Scientific Advisory Board for Neurotrack. R.F.B is funded by grants from the NIH K99/R00 (R00AG061238) and the Alzheimer’s Association. Y.T.Q is funded by grants from the NIH NIA (R01 AG054671, R01AG066823), the Alzheimer’s Association, and Massachusetts General Hospital ECOR, and has served as a paid consultant for Biogen. K.A.J. has served as paid consultant for Janssen, Genzyme, Novartis, Biogen, Roche, and AC Immune. He is a site co-investigator for Lilly/Avid and Janssen, and receives research support for clinical trials from Eisai, Lilly and Cerveau. K.A.J. received funding from NIH grants R01 EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, P01 AG036694, R13 AG042201174210, R01 AG027435, and R01 AG037497 and the Alzheimer’s Association grant ZEN-10-174210. RAS has served as a paid consultant for AC Immune, Acumen, Alnylam, Biogen, Cytox, Genentech, Ionis, Janssen, JOMDD, Neuraly, Neurocentria, Oligomerix, Prothena, Renew, Roche, Shionogi and receives research support for clinical trials from Alzheimer’s Association, Eisai, Eli Lilly and Co. and NIA. She also receives research support from the following grant: P01 AG036694, U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, K24 AG0350007, P50 AG005134, U19 AG010483, R01 AG027435, Fidelity Biosciences, Harvard NeuroDiscovery Center and the Alzheimer’s Association. These relationships are not related to the content in the manuscript. All other authors report no relevant conflicts.